TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Poland ,America ,American ,Polish ,Susan Galbraith ,Brendan Mcevoy ,Daiichi Sankyo ,Chelsea Ford ,Astrazeneca ,World Health Organisation ,International Agency For Research On Cancer ,Lungevity Foundation ,Single Institution Study ,Lung Ambition Alliance ,Drug Administration ,New Drug Application ,Priority Review ,Prescription Drug User Fee Act ,Executive Vice President ,Presidential Symposium ,International Association ,Lung Cancer ,Prescription Information ,Patient Information ,South America ,Rare Diseases ,Accessed September ,International Agency ,Lung Fact ,Small Cell ,Histological Samples ,Non Small Cell Lung Cancer ,Systematic Review ,Intj Clin Exp ,Clinical Oncology Provisional Opinion ,Epidermal Growth Factor Receptor ,Mutation Testing ,Kinase Inhibitor ,Available Methods ,Their Use ,Tumour Tissue ,Cytology Samples ,Mediated Resistance ,Business Wire ,Region ,